Zurzuvae (Zuranolone): What to Know About the New FDA-Approved Postpartum Depression Pill

Zurzuvae, also known by its generic name zuranolone, is an oral medication approved by the FDA in August 2023 specifically for the treatment of postpartum depression. Designed as a short-course therapy, it is prescribed when appropriate as a once‑daily medication for 14 days.

Zurzuvae is a synthetic hormone replacement of allopregnanolone, which is a naturally occurring neurosteroid produced in the brain from the hormone progesterone. Low levels of allopregnanolone have been associated with depressed mood. Because allopregnanolone production is associated with progesterone, the dramatic drop of progesterone post-delivery leads to a correlating drop in allopregnanolone, which is believed to contribute to the development of postpartum depression.

Zurzuvae is unique among antidepressants as a neurosteroid, but also in its proposed mechanism of action. It acts as a positive allosteric modulator of GABA-A receptors in the brain. Zurzuvae enhances the effect of the neurotransmitter GABA (gamma-aminobutyric acid), the brain’s primary inhibitory neurotransmitter, which helps restore balance in neural circuits that are disrupted in postpartum depression. Zurzuvae’s mechanism is thought to target these neurochemical imbalances more directly and rapidly than traditional treatments.

Zulresso (Brexanolone) made history in 2019 as the first FDA-approved medication for the treatment of PPD. Despite this milestone, its use was significantly limited by the requirement for a continuous 60‑hour intravenous infusion administered in a hospital or clinic setting, which often necessitated prolonged separation from family and newborns during a critical postpartum period. Zulresso was discontinued in 2025; however, the same neuroactive steroid pathway is now targeted by Zurzuvae in a more accessible oral formulation.

Clinicians have traditionally prescribed SSRIs as part of PPD treatment. The mechanisms of action of SSRIs primarily relate to their action on serotonin receptors, and while effective, often take 4 to 6 weeks of daily dosing to demonstrate an improvement in the mothers’ symptoms.

In contrast, many participants taking Zurzuvae in clinical trials reported symptom improvement within the first few days. Additionally, Zuranolone is administered as a 2-week daily oral dose and does not require ongoing treatment like SSRIs. Some clinical studies suggest that zuranolone has this rapid impact by targeting the hormone‑related mechanisms and having direct effects on postpartum hormonal changes.

For those affected by postpartum depression, this new drug may offer hope, reduce stigma, and increase willingness to take the medication.

A recent FDA announcement highlighted Zurzuvae’s distinctively swift action and efficacy in trials, indicating that some individuals experienced rapid and sustained improvement while taking the medication.

Its approval is considered by many clinicians to be an important development in mental health care and may provide a treatment option for women experiencing postpartum depression.

Additionally, as an acute therapy administered for just two weeks, Zurzuvae is particularly attractive for patients who prefer not to commit to long-term maintenance therapy. Its rapid action, often improving symptoms within 3 days to 1 week in clinical trials, can be an advantage over traditional medication and psychotherapy treatments that may take weeks to see improvement.

Zurzuvae’s approval doesn’t eclipse other treatment avenues for postpartum depression. Every individual is unique, and the treatment must be tailored to personal needs and preferences. Options range from individual or group therapy to cognitive behavioral approaches, family therapy, or alternative treatments. LifeStance offers an array of services catering to individual needs and believes that every woman should have access to the mental health care that suits her best.

Some of these services include:

• Anti-anxiety or antidepressant medications
• Psychotherapy
• Participation in a group setting for emotional support and education

Postpartum depression is a complex and sensitive issue. Recognizing symptoms early and understanding the range of available treatment options are essential steps in PPD recovery.

Medications, including Zurzuvae, may show promise for some based on clinical research. Lifestyle changes may also complement clinical treatment, including healthy habits and general tips for managing depression.

If you or someone you know is struggling with symptoms of postpartum depression, LifeStance can help connect you with a qualified provider.

If you or someone you know may be struggling with suicidal thoughts, dial 988 to reach the Suicide & Crisis Lifeline.

The information in this article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Medications are prescribed only when clinically appropriate and should be taken only as directed by a licensed clinician. Individual experiences with medications vary, and any potential risks or benefits depend on each person’s medical and psychological history.

What is the cost of Zurzuvae for postpartum depression?
The cost of Zurzuvae may vary depending on insurance coverage and pharmacy location. Without insurance, the list price is expected to be significant, but many patients may have access to manufacturer assistance programs or insurance coverage options. If you have questions about Zurzuvae cost, discuss your options with your healthcare provider and pharmacist.

What are the side effects of Zurzuvae?
Possible side effects of Zurzuvae may include drowsiness, dizziness, fatigue, and in rare instances, a risk of impaired attention or driving ability. Each patient should discuss all potential risks with a healthcare provider prior to starting this medication. Providers will evaluate you for safety before prescribing Zurzuvae. Always report concerning side effects promptly.

Can you take Zurzuvae while breastfeeding?
The information available on Zurzuvae while breastfeeding is limited. Some early data suggests that only a small amount may pass into breast milk. For individuals experiencing postpartum depression, untreated symptoms can have meaningful impacts on both mother and baby. The potential benefits of treatment may outweigh potential risks for some. If you are breastfeeding or planning to breastfeed, it’s important to discuss the possible risks and benefits with your provider so you can make an informed decision together.